Tilray’s CC Pharma Recognized as a TOP 100 Innovator in Germany

CC Pharma’s selection as a TOP 100 Innovator reflects its disciplined innovation strategy, strong regional footprint, and commitment to operational excellence in a highly regulated market. The award ...
WDTN

Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data ...
Nasdaq

Cocrystal Pharma Announces Enrollment Extension in Phase 2a Study of Influenza Treatment CC-42344 Due to Low Infection Rates

Data indicates a favorable safety and tolerability profile for CC-42344, with no serious adverse events or drug-related discontinuations reported. Extension of enrollment in the Phase 2a study allows ...
Seeking Alpha

Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam ...
Seeking Alpha

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent ...